Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05653752 · ClinicalTrials.gov registry record · Phase 1
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
A Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by MediLink Therapeutics (Suzhou) Co..
- Active
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 13
- Study locations
NCT05653752: Active Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by MediLink Therapeutics (Suzhou) Co..
NCT05653752 is a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer that is active but no longer recruiting, run by MediLink Therapeutics (Suzhou) Co.. The registered enrollment target is 80 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 13 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05653752, a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by MediLink Therapeutics (Suzhou) Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a phase 1, multicenter, open-label, first-in-human study of YL202 conducted in the United States and China. The study will evaluate the safety and tolerability of YL202 in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated NSCLC or hormone receptor (HR)-positive and HER2-negative BC, which have been heavily treated by standard treatment.
Conditions Studied
Interventions
- DRUG YL202
Study Locations (13)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- Next Oncology-Dallas - Irving
- UT health east Texas HOPE Cancer Center - Tyler
Zhejiang
- The First Affiliated Hospital of Zhejiang University School of Medicine - Hangzhou
- Zhejiang Cancer Hospital - Hangzhou
- Taizhou Hospital of Zhejiang Province - Taizhou
Florida
- BRCR Global - Plantation
Michigan
- Karmanos Cancer Institute - Detroit
Virginia
- Next Oncology-Virginia - Fairfax
Washington
- Summit Cancer Center - Spokane Valley
Fujian
- Fujian Cancer Hospital - Fuzhou
Hunan
- Hunan Cancer Hospital - Changsha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2022-12-20 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What the registry record for NCT05653752 still lists
NCT05653752 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which YL202 is the first listed.
NCT05653752 lists 13 locations in 9 states (Texas, Zhejiang, Florida).
Frequently Asked Questions
What is clinical trial NCT05653752 about?
NCT05653752 is a clinical study titled "A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer". This is a phase 1, multicenter, open-label, first-in-human study of YL202 conducted in the United States and China. The study will evaluate the safety and tolerability of YL202 in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated NSCLC or hormone receptor ...
What is the current status of trial NCT05653752?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2022-12-20. Estimated completion is 2026-12.
What conditions does trial NCT05653752 study?
This clinical trial studies the following conditions: Breast Cancer, Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05653752?
The interventions under investigation include: YL202 (DRUG).
Who is sponsoring clinical trial NCT05653752?
This trial is sponsored by MediLink Therapeutics (Suzhou) Co., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05653752 being conducted?
This trial has 13 study locations across Florida, Michigan, Texas, Virginia, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05653752's enrollment target sits among peer trials
80 649th of 1224 higher than 566 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI